223 related articles for article (PubMed ID: 37259024)
1. Thrombopoietin receptor agonist antibody for treating chemotherapy-induced thrombocytopenia.
Shin J; Kim MJ; Quan X; Kim JW; Lee S; Park S; Jeong JY; Yea K
BMC Cancer; 2023 May; 23(1):490. PubMed ID: 37259024
[TBL] [Abstract][Full Text] [Related]
2. [Consensus on clinical diagnosis, treatment and prevention management of chemotherapy induced thrombocytopenia in China(2018)].
Consensus Committee of Chemotherapy Induced Thrombocytopenia, Chinese Society of Clinical Oncology
Zhonghua Zhong Liu Za Zhi; 2018 Sep; 40(9):714-720. PubMed ID: 30293399
[TBL] [Abstract][Full Text] [Related]
3. Regulation of platelet lifespan in the presence and absence of thrombopoietin signaling.
Lebois M; Dowling MR; Gangatirkar P; Hodgkin PD; Kile BT; Alexander WS; Josefsson EC
J Thromb Haemost; 2016 Sep; 14(9):1882-7. PubMed ID: 27344013
[TBL] [Abstract][Full Text] [Related]
4. Discovery of a novel megakaryopoiesis enhancer, ingenol, promoting thrombopoiesis through PI3K-Akt signaling independent of thrombopoietin.
Wang L; Zhang T; Liu S; Mo Q; Jiang N; Chen Q; Yang J; Han YW; Chen JP; Huang FH; Li H; Zhou J; Luo JS; Wu JM
Pharmacol Res; 2022 Mar; 177():106096. PubMed ID: 35077844
[TBL] [Abstract][Full Text] [Related]
5. The effect of a novel, small non-peptidyl molecule butyzamide on human thrombopoietin receptor and megakaryopoiesis.
Nogami W; Yoshida H; Koizumi K; Yamada H; Abe K; Arimura A; Yamane N; Takahashi K; Yamane A; Oda A; Tanaka Y; Takemoto H; Ohnishi Y; Ikeda Y; Miyakawa Y
Haematologica; 2008 Oct; 93(10):1495-504. PubMed ID: 18728031
[TBL] [Abstract][Full Text] [Related]
6. Humanized VB22B minibody for human Mpl stimulates human megakaryopoiesis but does not enhance platelet aggregation.
Matsuki E; Miyakawa Y; Yamane A; Okamoto S
Exp Hematol; 2011 Aug; 39(8):829-36. PubMed ID: 21605620
[TBL] [Abstract][Full Text] [Related]
7. Anti-c-Mpl antibodies in immune thrombocytopenia suppress thrombopoiesis and decrease response to rhTPO.
Jing FM; Zhang XL; Meng FL; Liu XM; Shi Y; Qin P; Wang L; Zhou H; Hou Y; Song Q; Peng J; Hou M
Thromb Res; 2018 Oct; 170():200-206. PubMed ID: 30199786
[TBL] [Abstract][Full Text] [Related]
8. Milestones in understanding platelet production: a historical overview.
Kuter DJ
Br J Haematol; 2014 Apr; 165(2):248-58. PubMed ID: 24528208
[TBL] [Abstract][Full Text] [Related]
9. Thrombocytopenia in HIV infection: impairment of platelet formation and loss correlates with increased c-Mpl and ligand thrombopoietin expression.
Sundell IB; Koka PS
Curr HIV Res; 2006 Jan; 4(1):107-16. PubMed ID: 16454716
[TBL] [Abstract][Full Text] [Related]
10. Romiplostim: a second-generation thrombopoietin agonist.
Cohn CS; Bussel JB
Drugs Today (Barc); 2009 Mar; 45(3):175-88. PubMed ID: 19436840
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human thrombopoietin: basic biology and evaluation of clinical studies.
Kuter DJ; Begley CG
Blood; 2002 Nov; 100(10):3457-69. PubMed ID: 12411315
[TBL] [Abstract][Full Text] [Related]
12. Targeting a thrombopoietin-independent strategy in the discovery of a novel inducer of megakaryocytopoiesis, DMAG, for the treatment of thrombocytopenia.
Wang L; Liu S; Luo J; Mo Q; Ran M; Zhang T; Li X; Zou W; Mei Q; Chen J; Yang J; Zeng J; Huang F; Wu A; Zhang C; Wu J
Haematologica; 2023 May; 108(5):1394-1411. PubMed ID: 36546424
[TBL] [Abstract][Full Text] [Related]
13. Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation.
Ng AP; Kauppi M; Metcalf D; Hyland CD; Josefsson EC; Lebois M; Zhang JG; Baldwin TM; Di Rago L; Hilton DJ; Alexander WS
Proc Natl Acad Sci U S A; 2014 Apr; 111(16):5884-9. PubMed ID: 24711413
[TBL] [Abstract][Full Text] [Related]
14. The biology of thrombopoietin and thrombopoietin receptor agonists.
Kuter DJ
Int J Hematol; 2013 Jul; 98(1):10-23. PubMed ID: 23821332
[TBL] [Abstract][Full Text] [Related]
15. F104S c-Mpl responds to a transmembrane domain-binding thrombopoietin receptor agonist: proof of concept that selected receptor mutations in congenital amegakaryocytic thrombocytopenia can be stimulated with alternative thrombopoietic agents.
Fox NE; Lim J; Chen R; Geddis AE
Exp Hematol; 2010 May; 38(5):384-91. PubMed ID: 20188141
[TBL] [Abstract][Full Text] [Related]
16. A real-world observation on thrombopoietic agents for patients with cancer treatment-induced thrombocytopenia in China: A multicenter, cross-sectional study.
Chen M; Li L; Xia Q; Chen X; Liao Z; Wang C; Shen B; Zhou M; Zhang Q; Zhang Y; Qian L; Yuan X; Wang Z; Xue C; An X; Liu B; Gu K; Hou M; Wang X; Wang W; Li E; Zhong J; Cheng J; Shu Y; Yang N; Wang H; Yang R; Liu T; Deng T; Ma F; Liao W; Qiu W; Chen Y; Chen X; Zhang M; Xu R; Li X; Feng J; Ba Y; Shi Y
Cancer; 2024 Apr; 130(S8):1524-1538. PubMed ID: 38515388
[TBL] [Abstract][Full Text] [Related]
17. Clinical experience with recombinant human thrombopoietin in chemotherapy-induced thrombocytopenia.
Vadhan-Raj S
Semin Hematol; 2000 Apr; 37(2 Suppl 4):28-34. PubMed ID: 10831286
[TBL] [Abstract][Full Text] [Related]
18. [A multi-center clinical trial of recombinant human thrombopoietin in the treatment of chemotherapy-induced thrombocytopenia in patients with solid tumor].
Bai CM; Xu GX; Zhao YQ; Han SM; Shan YD
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Aug; 26(4):437-41. PubMed ID: 15379272
[TBL] [Abstract][Full Text] [Related]
19. [The clinical study of recombinant human thrombopoietin in the treatment of chemotherapy-induced severe thrombocytopenia].
Bai CM; Zou XY; Zhao YQ; Han SM; Shan YD;
Zhonghua Yi Xue Za Zhi; 2004 Mar; 84(5):397-400. PubMed ID: 15061993
[TBL] [Abstract][Full Text] [Related]
20. Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia.
Soff GA; Ray-Coquard I; Rivera LJM; Fryzek J; Mullins M; Bylsma LC; Park JK
PLoS One; 2022; 17(6):e0257673. PubMed ID: 35679540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
